Search results
Showing 706 to 720 of 1070 results for drug therapy
Cardiovascular risk assessment and lipid modification (QS100)
This quality standard covers identifying and assessing cardiovascular risk in adults without cardiovascular disease, and treatment to prevent primary and secondary cardiovascular disease. It describes high-quality care in priority areas for improvement.
View quality statements for QS100Show all sections
Sections for QS100
- Quality statements
- Quality statement 1: Identifying adults who are likely to be at high risk
- Quality statement 2: Diet and lifestyle advice for primary prevention
- Quality statement 3: Lipid-lowering treatment for primary prevention
- Quality statement 4: Assessing response to lipid-lowering treatment
- Quality statement 5: Secondary prevention of cardiovascular disease
- Update information
- About this quality standard
Functional electrical stimulation for drop foot of central neurological origin (HTG178)
Evidence-based recommendations on functional electrical stimulation for drop foot of central neurological origin. This involves stimulating the peripheral nerves that supply the paralysed muscle using electrodes to restore muscular function.
View recommendations for HTG178Show all sections
Sections for HTG178
Evidence-based recommendations on inotuzumab ozogamicin (Besponsa) for relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) for relapsed or refractory classical Hodgkin lymphoma in people 3 years and over.
Evidence-based recommendations on relugolix–estradiol–norethisterone acetate (Ryeqo) for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age.
eazyplex SuperBug kits for detecting carbapenemase-producing organisms (MIB94)
NICE has developed a medtech innovation briefing (MIB) on eazyplex SuperBug kits for detecting carbapenemase-producing organisms .
Evidence-based recommendations on apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults.
This quality standard covers preventing and controlling infection in adults, young people and children receiving healthcare in primary, community and secondary care settings. It includes preventing healthcare-associated infections that develop because of treatment or from being in a healthcare setting. It describes high-quality care in priority areas for improvement.
View quality statements for QS61Show all sections
Sections for QS61
- Quality statements
- Quality statement 1: Antimicrobial stewardship
- Quality statement 2: Organisational responsibility
- Quality statement 3: Hand decontamination
- Quality statement 4: Urinary catheters
- Quality statement 5: Vascular access devices
- Quality statement 6: Educating people about infection prevention and control
- Update information
Evidence-based recommendations on on regorafenib (Stivarga) for previously treated gastrointestinal stromal tumours in adults.
Aflibercept solution for injection for treating wet age‑related macular degeneration (TA294)
Evidence-based recommendations on aflibercept solution for injection (Eylea) for treating wet age-related macular degeneration in adults.
who have had unsuccessful first surgery, and very limited evidence on drug therapy with cinacalcet compared with placebo. The committee...
NICE has developed a medtech innovation briefing (MIB) on FreeStyle Libre for glucose monitoring .
LATITUDE NXT Patient Management System for monitoring cardiac devices at home (MIB67)
NICE has developed a medtech innovation briefing (MIB) on the LATITUDE NXT Patient Management System for monitoring cardiac devices at home
Evidence-based recommendations on entecavir for treating chronic hepatitis B in adults.
Evidence-based recommendations on blinatumomab (Blincyto) for treating Philadelphia-chromosome-negative precursor B-cell acute lymphoblastic leukaemia in adults.